Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology (EPIDOCAVILH)

17 listopada 2026 zaktualizowane przez: Poitiers University Hospital

Pilot Study for the Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology

In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.

Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.

In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.

Przegląd badań

Szczegółowy opis

This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

30

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Patient ≥ 18 years old.
  • Consultation for treatment initiation (first-line or relapse) for gynecological, digestive, urological, or hematological cancer.
  • Patient experiencing pain related to a cancer pathology (pain numerical rating scale ≥ 1) for less than 3 months.
  • Patient receiving outpatient cancer treatment at the Châtellerault site of Poitiers University Hospital.
  • Patient declaring having a general practitioner.
  • Patient's general practitioner agreeing to participate in the study.
  • Patient covered by the French social Security system or through a third party.

Non-Inclusion Criteria:

  • Patient already receiving care for this pain from the reference pain center or supportive care team.
  • Patient unable to understand, write, or speak French.
  • Patient diagnosed with uncontrolled psychiatric disorders.
  • Patient with chronic pain unrelated to cancer.
  • Pain related to therapeutic procedures.
  • Patient residing in a medicalized facility.
  • Patient under enhanced protection, including: minors, pregnant or breastfeeding women, individuals deprived of liberty by judicial or administrative decision, individuals staying in a healthcare or social institution, adults under legal protection (guardianship, curatorship, or subordination), patients in emergency situations.
  • Patient with a significant impairment of general condition (ECOG-PS > 2, Eastern Cooperative Oncology Group Performance Status) or cognitive disorders.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Badania usług zdrowotnych
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Early management of acute pain

Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP.

Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary.

Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms.

Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study).

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Proportion of eligible patients that provide a consent to participate
Ramy czasowe: 1 day

Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent.

1 day
Proportion of general pactitioner that confirmed their participation
Ramy czasowe: 2 days

General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation.

2 days
Proportion of consultations with the general practitioner performed
Ramy czasowe: 28 days

Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed.

28 days
Proportion of consultations at the hospital performed
Ramy czasowe: 28 days

Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed.

28 days

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in pain severity after 28 days
Ramy czasowe: 28 days

Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain).

28 days
Change in pain interference after 28 days
Ramy czasowe: 28 days

Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain).

28 days
Change in quality of life after 28 days
Ramy czasowe: 28 days

Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life).

28 days
Proportion of patients requiring a specific pain management
Ramy czasowe: 28 days

Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team.

28 days
Global satisfaction of the patients
Ramy czasowe: 28 days

Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied")

28 days
Proportion of patients with a modified prescription by the general practitioner for analgesics treatments
Ramy czasowe: 28 days

The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch

28 days

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 stycznia 2027

Zakończenie podstawowe (Szacowany)

31 stycznia 2028

Ukończenie studiów (Szacowany)

31 grudnia 2028

Daty rejestracji na studia

Pierwszy przesłany

20 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

17 listopada 2026

Pierwszy wysłany (Rzeczywisty)

19 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

17 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj